Cooley LLP announced today that it advised Portola Pharmaceuticals on its $140 million initial public offering. Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. It now trades on the NASDAQ Global Stock Market under the symbol “PTLA.”
The Cooley corporate securities team advising Portola was comprised of partners Robert Jones, Kenn Guernsey and Sally Kay and associates Christine Liu, Steven Hwang, David Ambler and Matt Fleming. Critical support for the offering was provided by partner Lila Hope and associates Bin Wang and Tracy Huang Harrison (Life Sciences), partner Natasha Leskovsek (Regulatory), partner Amy Wood and associates Keith Ranta and Justin Ho (Compensation & Benefits) and partners Susan Cooper Philpot and Bill Morrow (Tax).
Related Posts:
- Cooley Represents AcelRx Pharmaceuticals in Public Offering
- Atara Completes its Initial Public Offering
- Cooley Advises Xencor on its Initial Public Offering
- Cooley Advises Versartis on its $145 Million IPO
- Cooley Advises Underwriters on LinkedIn’s $1.25 Billion Follow-On Offering
